Comparison of clinical characteristics and antibiotic susceptibility between Pseudomonas aeruginosa and P. putida keratitis at a tertiary referral center: a retrospective study

Table 2 Clinical characteristics and treatment outcomes of Pseudomonas aeruginosa and P. putida keratitis

Characteristics	P. aeruginosa (n = 33)	P. putida (n = 16)	p-value (x²-test)
Central lesion^‡	24 (72.7)	12 (75.0)	1.000*
Epithelial defect size ≥5 mm²	21 (63.6)	9 (56.3)	0.619
Hypopyon	15 (45.5)	1 (6.3)	0.006
Epithelial healing time ≥ 10 days	20 (60.6)	9 (56.3)	0.771
Complications**	5 (15.2)	3 (18.8)	1.000*
Surgical treatment⁺⁺	5 (15.2)	2 (12.5)	1.000*
Presenting BCVA^§
mean ± SD, logMAR	1.66 ± 0.95	1.53 ± 1.10	0.675^†
< 0.1, Snellen	20 (62.5)	9 (56.3)	0.676
Final BCVA^§
mean ± SD, logMAR	0.98 ± 1.12	1.09 ± 1.22	0.760^†
< 0.1, Snellen	9 (28.1)	6 (37.5)	0.509
Decreased BCVA^#§	8 (25.0)	5 (31.3)	0.735*
Clinical outcome^§¶
Good	11 (34.4)	7 (43.8)	0.527
Moderate	11 (34.4)	3 (18.8)	0.328*
Poor	10 (31.2)	6 (37.5)	0.665

BCVA best corrected visual acuity, logMAR logarithm of the minimum angle of resolution, SD standard deviation
Values indicate numbers (proportion) unless otherwise noted
*The p-value was calculated using Fisher’s exact test
^†The p-value was calculated using independent t-test
^‡Corneal lesion is located within the 1/2 radius from the center of the cornea
**Complicated cases in P. aeruginosa group were persistent epithelial defect (two cases), impending corneal perforation (two cases), and progression of infection (one case); those in P. putida group was persistent epithelial defect (three cases)
⁺⁺Surgical treatment cases in P. aeruginosa group were amniotic membrane transplantation (three cases), tarsorrhaphy (one case), and evisceration (one case); those in P. putida group was amniotic membrane transplantation (two cases)
^§Total n = 48: One young child in the P. aeruginosa group who could not read letters was excluded
^#Cases of final BCVA worsened from presentation
^¶The clinical outcomes were assessed at the end of three months or at the completion of treatment and classified into three groups, as defined by Green [11].

ISSN: 1471-2415